Literature DB >> 24983982

Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity.

Jin-Feng Lin1, Jin-Min Chen, Jun-Hua Zuo, Allen Yu, Zhu-Jun Xiao, Fei-Hong Deng, Biao Nie, Bo Jiang.   

Abstract

BACKGROUND: Fecal calprotectin (FC) is a promising biomarker for diagnosis of inflammatory bowel disease (IBD). However, the utility of FC for assessment of IBD activity has yet to be clearly demonstrated. The aim of our study was to evaluate the diagnostic accuracy of FC for differentiating between patients with active IBD and those in remission.
METHODS: We systematically searched the databases Medline, Web of Science, Cochrane Library, and EMBASE for eligible studies from December 2013 or earlier that evaluated activity in ulcerative colitis (UC) and Crohn's disease (CD). A hierarchical summary receiver operating characteristic model was performed to calculate the area under the curve to evaluate the overall diagnostic accuracy. The sensitivities and specificities of each commonly applied cutoff value were pooled using a random effects model.
RESULTS: We included 13 studies (744 patients with UC and 727 with CD) in the final analysis. The area under the curve values were 0.89 (95% confidence interval, 0.86-0.92), 0.93 (0.89-0.97), and 0.88 (0.83-0.93) in the IBD, UC, and CD groups, respectively. For the IBD group at a cutoff value of 50 μg/g, the pooled sensitivity was 0.92 (0.90-0.94) and specificity 0.60 (0.52-0.67). For a cutoff value at 100 μg/g, the pooled sensitivity was 0.84 (0.80-0.88) and specificity was 0.66 (0.59-0.73). For a cutoff value at 250 μg/g, the pooled sensitivity was 0.80 (0.76-0.84) and specificity was 0.82 (0.77-0.86).
CONCLUSIONS: The FC test is a reliable marker for assessing IBD disease activity and may have greater ability to evaluate disease activity in UC than CD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24983982     DOI: 10.1097/MIB.0000000000000057

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  88 in total

1.  Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; GianMarco Giorgetti; Giovanni Brandimarte
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

Review 2.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

3.  High-fat diet induced leptin and Wnt expression: RNA-sequencing and pathway analysis of mouse colonic tissue and tumors.

Authors:  Harrison M Penrose; Sandra Heller; Chloe Cable; Hani Nakhoul; Melody Baddoo; Erik Flemington; Susan E Crawford; Suzana D Savkovic
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

Review 4.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

5.  Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease.

Authors:  James D Lewis; Eric Z Chen; Robert N Baldassano; Anthony R Otley; Anne M Griffiths; Dale Lee; Kyle Bittinger; Aubrey Bailey; Elliot S Friedman; Christian Hoffmann; Lindsey Albenberg; Rohini Sinha; Charlene Compher; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Hongzhe Li; Gary D Wu; Frederic D Bushman
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

Review 6.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

Review 7.  Utility of Biomarkers in the Management of Inflammatory Bowel Disease.

Authors:  Gursimran Kochhar; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 8.  Gut inflammation and microbiome in spondyloarthritis.

Authors:  Jayakanthan Kabeerdoss; Pulukool Sandhya; Debashish Danda
Journal:  Rheumatol Int       Date:  2015-12-30       Impact factor: 2.631

9.  Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.

Authors:  Chloé Maréchal; Isabelle Aimone-Gastin; Cédric Baumann; Bastien Dirrenberger; Jean-Louis Guéant; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2017-02-06       Impact factor: 4.623

Review 10.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Mahmoud H Mosli; Guangyong Zou; Sushil K Garg; Sean G Feagan; John K MacDonald; Nilesh Chande; William J Sandborn; Brian G Feagan
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.